

FOR ILLUSTRATIVE
PURPOSES ONLY



1 PATIENT INFORMATION

Name (first, last) Donald Smith				
Home address 123 North Way Road		City Centerville	State PA	Zip 86324
Primary phone 878-555-1234		Patient date of birth (mm/dd/yyyy): 03 / 09 / 1965		
Alternate phone 878-555-0141		Gender (check one): Male <input checked="" type="checkbox"/> Female <input type="checkbox"/>		
Primary language (check one): English <input checked="" type="checkbox"/> Spanish <input type="checkbox"/> Other <input type="checkbox"/>		Drug allergies None		



2 PRACTICE INFORMATION

Practice name Dental Professionals, Inc.		Prescriber name Susan Jones, DDS		
Office contact name Marylou Brown		Office contact email mbrown@netmail.com		
Phone # 878-555-1212	Fax # 878-555-4141	Preferred method of communication (check one): Phone <input checked="" type="checkbox"/> Fax <input type="checkbox"/>		
Deliver to address 4100 West Boulevard, Suite 220		City Middletown	State PA	Zip 86324
NPI # 1234567890		Today's date (mm/dd/yyyy): 01 / 13 / 2018		

! **IMPORTANT SHIPPING INFORMATION:** Please note that product will be delivered within 14 business days of the prescription submission date if all required information is obtained. Product will always be delivered to the prescriber, Tuesday through Friday, except on major holidays or the day following a major holiday.



3 PRESCRIPTION BENEFIT INSURANCE

PRIMARY MEDICAL INSURANCE

Prescription insurance RX Prescription Drug Card		Medical insurance Aetna		
Insured name Donald Smith		Insured name Donald Smith		
Drug cardholder ID # 0123456789		Policy # W1999 45454		
Group # 12345678		Group # 12345-123-00001		
Bin # 123456	Rx PCN # 1234	Member services phone # 888-555-1234		
Phone # N/A				

CHECK HERE to provide patient quote to purchase medication directly from the pharmacy in the event the patient's benefit design does not cover the medication.

4 PRESCRIPTION

The dental practitioner prescribing ARESTIN will determine the appropriate course of therapy for the patient. Each prescription is a 30-day supply with no refills; a new prescription is required for each order. The prescription is for the patient listed on the prescription form and cannot be resold or used for any other patient.

Complete the following prescription prior to faxing. *The quantity dispensed represents no greater than a 30-day supply. New York Prescribers may attach an official NY prescription.*

ARESTIN® (minocycline hydrochloride) Microspheres, 1mg Cartridges

SIG: For administration by the dental practitioner into the periodontal pocket only for the treatment of adult periodontitis

Quantity: 24 cartridge(s) (1 cartridge per site diagnosed)

X <u>Susan Jones</u>	X _____	<u>01/13/2018</u>
Prescriber signature (DO NOT STAMP)	Prescriber signature (DO NOT STAMP)	Date (mm/dd/yyyy)
Dispense as written	Substitution permissible	

Please see accompanying full Prescribing Information for ARESTIN.

5 PRESCRIBER CONSENT: Check box below to confirm authorization was obtained

My signature indicates my authorization for BioSolutia Pharmaceutical Services, LLC (Business Associate or BA), as the operator of the ARESTIN Rx Access™ program, to obtain, use and disclose protected health information as defined in 45 CFR 160.103 (PHI) about my patients, to and from (i) patient's insurer, including eligibility and other benefit information, for my payment and/or healthcare operation purposes and (ii) healthcare providers, such as specialty pharmacies (SPs), for treatment purposes, including to forward the prescription and associated PHI to a valid SP and to track the status of medications dispensed by SPs for my patients for coordination of care and related purposes. BA may de-identify, use and disclose PHI of my patients to the extent allowed by 45 CFR 164.504, provided that the de-identification complies with the requirements of 45 CFR 164.514(b). BA shall maintain administrative, technical and physical safeguards to ensure the availability, integrity and confidentiality of PHI and shall notify me of any impermissible use or disclosure Security Incident and Breach of Unsecured PHI as required by law. This agreement incorporates and BA agrees to comply with requirements of 45 CFR 164.504 and 164.314(a)(2). This BA agreement shall terminate upon any material violation of this agreement by BA, upon the written request of physician, or two years after the signature date below. Upon termination, BA shall destroy PHI in its possession.

CHECK HERE: I have received oral authorization from my patient to act as his/her agent for the delivery receipt, storage, and administration of his/her ARESTIN prescription medication

X <u>Susan Jones</u>	X <u>Susan Jones</u>	<u>01/13/2018</u>
Prescriber name	Prescriber signature (DO NOT STAMP)	Date (mm/dd/yyyy)



Submit copies of front/
back of BOTH cards

PRESCRIPTION FORM INSTRUCTIONS/GLOSSARY OF TERMS

The following information is provided to help dental professionals and office associates participating in the ARESTIN Rx Access™ program correctly complete and submit the ARESTIN Prescription Form.

PATIENT GENDER AND DATE OF BIRTH

Patient Gender and **Date of Birth** are identifiers within the patient's prescription benefit plan. They must be included to verify benefit eligibility and copay if coverage is available.

DOCTOR'S NPI#

New federal regulations require that all prescriptions are submitted with the **doctor's NPI#**, not a practice NPI#.

Rx PCN#

ARESTIN is being billed through the patient's prescription drug benefit plan. The **plan's information is mandatory** to obtain benefit eligibility.

Arestin minocycline HCl 1mg MICROSPHERES
Fax 855.630.9783 Phone 855.684.7481
FORM 1 of 2
Fax both forms together
All fields required for submission

1 PATIENT INFORMATION

Name (first, last) Donald Smith
Home address 123 North Way Road
City Centerville State PA Zip 86324
Primary phone 878-555-1234
Patient date of birth (mm/dd/yyyy) 03 / 09 / 1965
Alternate phone 878-555-0141
Gender (check one): Male Female
Primary language (check one): English Spanish Other
Drug allergies None

2 PRACTICE INFORMATION

Practice name Dental Professionals, Inc. Prescriber name Susan Jones, DDS
Office contact name Marylou Brown Office contact email mbrown@netmail.com
Phone # 878-555-1212 Fax # 878-555-4141 Preferred method of communication (check one): Phone Fax
Deliver to address 4100 West Boulevard, Suite 220 City Middletown State PA Zip 86324
NPI # 1234567890 Today's date (mm/dd/yyyy) 01 / 13 / 2018

3 PRESCRIPTION BENEFIT INSURANCE

Prescription insurance RX Prescription Drug Card
Insured name Donald Smith
Drug cardholder ID # 0123456789
Group # 12345678
Bin # 123456
Phone # N/A
Rx PCN # 1234

PRIMARY MEDICAL INSURANCE

Medical insurance Aetna
Insured name Donald Smith
Policy # W1999 45454
Group # 12345-123-00001
Member services phone # 888-555-1234

Submit copies of front/back of BOTH cards

IMPORTANT SHIPPING INFORMATION: Please note that product will be delivered within 14 business days of the prescription submission date if all required information is obtained. Product will always be delivered to the prescriber, Monday through Friday, except on major holidays or the day following a major holiday.

CHECK HERE to provide patient quote to purchase medication directly from the pharmacy in the event the patient's benefit design does not cover the medication.

PATIENT Rx CARD

Both the Rx BIN# and PCN# are mandatory control numbers that specifically direct electronic pharmacy claims to be processed.

Rx Prescription Drug Card

Member: Donald Smith
ID Number: XYZ123456789
RxPCN: 1234
RxBIN: 123456
RxGrp: 12345678

Us exerrit oribus quas mos etur, ius everem. Qui dolo voluptat lacuMus ulleceate nullorehenihictum hillitit nobissi tassit verit apiducitur simus et et re endipsus etur sene cus seque voluptatestiae
1-888-555-1234

Us exerrit oribus quas mos etur, ius everem. Qui dolo voluptat lacuMus ulleceate nullorehenihictum hillitit nobissi tassit verit apiducitur simus et et re endipsus etur sene cus seque voluptatestiae

When a patient requests a prescription to be filled through a retail or specialty pharmacy, pertinent information is collected from the patient's prescription drug card:

- Name of Health Plan/Prescription Benefit Manager (PBM)
- Member or Cardholder ID#
- Member Group#
- Rx BIN#
- Rx PCN#

MEDICAL PLAN CARD

If the patient does not have a prescription drug card, a medical plan card can be used, or the prescription benefit information can be found on the medical plan card as shown:

Blue Advantage | HMO

Donald Smith Grp#: 12345-123-0001
ID NO: XYZ123456789 Rx BIN 12345
00 DONALD SMITH PCN 1234
PCP Name: Jonathan Q. Smith M D Rx V
PCP Copay: \$15 Y N Y Y

HELP IS JUST A PHONE CALL AWAY

Please contact ARESTIN Rx Access if you have any additional questions regarding proper completion of the ARESTIN Prescription Form.



ARESTIN Rx Access™ Service Center
1-855-684-7481
Monday through Friday
8AM to 8PM ET

ARESTIN®


(minocycline hydrochloride) microspheres, 1 mg

Rx only

DESCRIPTION

ARESTIN (minocycline hydrochloride) microspheres, 1 mg is a subgingival sustained-release product containing the antibiotic minocycline hydrochloride incorporated into a bioresorbable polymer, Poly (glycolide-co-dl-lactide) or PGLA, for professional subgingival administration into periodontal pockets. Each unit-dose cartridge delivers minocycline hydrochloride equivalent to 1 mg of minocycline free base.

The molecular formula of minocycline hydrochloride is $C_{23}H_{27}N_3O_7 \cdot HCl$, and the molecular weight is 493.94. The structural formula of minocycline hydrochloride is:



CLINICAL PHARMACOLOGY

Mechanism of Action

The mechanism of action of ARESTIN as an adjunct to scaling and root planing procedures for reduction of pocket depth in patients with adult periodontitis is unknown.

Microbiology

Minocycline, a member of the tetracycline class of antibiotics, has a broad spectrum of activity. It is bacteriostatic and exerts its antimicrobial activity by inhibiting protein synthesis. *In vitro* susceptibility testing has shown that the organisms *Porphyromonas gingivalis*, *Prevotella intermedia*, *Fusobacterium nucleatum*, *Eikenella corrodens*, and *Actinobacillus actinomycetemcomitans*, which are associated with periodontal disease, are susceptible to minocycline at concentrations of ≤ 8 mcg/mL; qualitative and quantitative changes in plaque microorganisms have not been demonstrated in subjects with periodontitis, using this product.

The emergence of minocycline-resistant bacteria in single-site plaque samples was studied in subjects before and after treatment with ARESTIN at 2 centers. There was a slight increase in the numbers of minocycline-resistant bacteria at the end of the 9-month study period; however, the number of subjects studied was small and the clinical significance of these findings is unknown.

The emergence of minocycline-resistant bacteria and changes in the presence of *Candida albicans* and *Staphylococcus aureus* in the gastrointestinal tract were studied in subjects treated with ARESTIN in one phase 3 study. No changes in the presence of minocycline-resistant bacteria or *Candida albicans* or *Staphylococcus aureus* were seen at the end of the 56-day study period.

Pharmacokinetics

In a pharmacokinetic study, 18 subjects (10 men and 8 women) with moderate to advanced chronic periodontitis were treated with a mean dose of 46.2 mg (25 to 112 unit doses) of ARESTIN. After fasting for at least 10 hours, subjects received subgingival application of ARESTIN (1 mg per treatment site) following scaling and root planing at a minimum of 30 sites on at least 8 teeth. Investigational drug was administered to all eligible sites ≥ 5 mm in probing depth. Mean dose normalized saliva AUC and C_{max} were found to be approximately 125 and 1000 times higher than those of serum parameters, respectively.

Clinical Studies

In 2 well-controlled, multicenter, investigator-blind, vehicle-controlled, parallel-design studies (3 arms), 748 subjects (study OPI-103A=368, study OPI-103B=380) with generalized moderate to advanced adult periodontitis characterized by a mean probing depth of 5.90 and 5.81 mm, respectively, were enrolled. Subjects received 1 of 3 treatments: (1) scaling and root planing (SRP), (2) SRP + vehicle (bioresorbable polymer, PGLA), and (3) SRP + ARESTIN. To qualify for the study, subjects were required to have 4 teeth with periodontal pockets of 6 to 9 mm that bled on probing. However, treatment was administered to all sites with mean probing depths of 5 mm or greater. Subjects studied were in good general health. Subjects with poor glycemic control or active infectious diseases were excluded from the studies. Retreatment occurred at 3 and 6 months after initial treatment, and any new site with pocket depth ≥ 5 mm also received treatment. Subjects treated with ARESTIN were found to have statistically significantly reduced probing pocket depth compared with those treated with SRP alone or SRP + vehicle at 9 months after initial treatment, as shown in Table 1.

Table 1: Probing Pocket Depth at Baseline and Change in Pocket Depth at 9 Months from 2 Multicenter US Clinical Trials

Time	Study OPI-103A N=368			Study OPI-103B N=380		
	SRP Alone n=124	SRP + Vehicle n=123	SRP + ARESTIN n=121	SRP Alone n=126	SRP + Vehicle n=126	SRP + ARESTIN n=128
PD (mm) at Baseline [Mean \pm SE]	5.88 ± 0.04	5.91 ± 0.04	5.88 ± 0.04	5.79 ± 0.03	5.82 ± 0.04	5.81 ± 0.04
PD (mm) Change from Baseline at 9 Months [Mean \pm SE]	-1.04 ± 0.07	-0.90 ± 0.54	-1.20 ^{††} ± 0.07	-1.32 ± 0.07	-1.30 ± 0.07	-1.63 ^{†††} ± 0.07

SE = standard error; SRP = scaling and root planing; PD = pocket depth

Significantly different from SRP: * ($P \leq 0.05$); ** ($P \leq 0.001$)

Significantly different from SRP + vehicle: † ($P \leq 0.001$)

In these 2 studies, an average of 29.5 (5-114), 31.7 (4-137), and 31 (5-108) sites were treated at baseline in the SRP alone, SRP + vehicle, and SRP + ARESTIN groups, respectively. When these studies are combined, the mean pocket depth change at 9 months was -1.18 mm, -1.10 mm, and -1.42 mm for SRP alone, SRP + vehicle, and SRP + ARESTIN, respectively.

Table 2: Numbers (Percentage) of Pockets Showing a Change of Pocket Depth ≥ 2 mm at 9 Months from 2 Multicenter US Clinical Trials

	Study OPI-103A			Study OPI-103B		
	SRP Alone	SRP + Vehicle	SRP + ARESTIN	SRP Alone	SRP + Vehicle	SRP + ARESTIN
Pockets ≥ 2 mm (% of Total)	1046 (31.1%)	927 (25.7%)	1326 (36.5%)	1692 (42.2%)	1710 (40.0%)	2082 (51.0%)
Pockets ≥ 3 mm (% of Total)	417 (12.4%)	315 (8.7%)	548 (15.1%)	553 (13.8%)	524 (12.3%)	704 (17.3%)

SRP + ARESTIN resulted in a greater percentage of pockets showing a change of PD ≥ 2 mm and ≥ 3 mm compared to SRP alone at 9 months, as shown in Table 2.

Table 3: Mean Pocket Depth Changes (SE) in Subpopulations, Studies 103A and 103B Combined

	SRP Alone	SRP + Vehicle	SRP + ARESTIN
Smokers	n=91 -0.96 (± 0.09) mm	n=90 -0.98 (± 0.07) mm	n=90 -1.24 (± 0.09) mm ^{**}
Nonsmokers	n=159 -1.31 (± 0.06) mm	n=159 -1.17 (± 0.07) mm	n=159 -1.53 (± 0.06) mm ^{**}
Subjects >50 YOA	n=21 -1.07 (± 0.09) mm	n=81 -0.92 (± 0.08) mm	n=107 -1.42 (± 0.08) mm ^{**}
Subjects ≤ 50 YOA	n=167 -1.24 (± 0.06) mm	n=168 -1.19 (± 0.06) mm	n=142 -1.43 (± 0.07) mm [*]
Subjects with CV Disease	n=36 -0.99 (± 0.13) mm	n=29 -1.06 (± 0.14) mm	n=36 -1.56 (± 0.14) mm ^{**}
Subjects without CV Disease	n=214 -1.22 (± 0.06) mm	n=220 -1.11 (± 0.05) mm	n=213 -1.40 (± 0.06) mm ^{**}

SRP = scaling and root planing; YOA = years of age; CV = cardiovascular

*SRP vs SRP + ARESTIN $P \leq 0.05$; **SRP vs SRP + ARESTIN $P \leq 0.001$

In both studies, the following patient subgroups were prospectively analyzed: smokers, subjects over and under 50 years of age, and subjects with a previous history of cardiovascular disease. The results of the combined studies are presented in Table 3.

In smokers, the mean reduction in pocket depth at 9 months was less in all treatment groups than in nonsmokers, but the reduction in mean pocket depth at 9 months with SRP + ARESTIN was significantly greater than with SRP + vehicle or SRP alone.

Table 4: Mean Pocket Depth Change in Subjects with Mean Baseline PD ≥ 5 mm, ≥ 6 mm, and ≥ 7 mm at 9 Months from 2 Multicenter US Clinical Trials

Mean Baseline Pocket Depth	Study OPI-103A			Study OPI-103B		
	SRP Alone	SRP + Vehicle	SRP + ARESTIN	SRP Alone	SRP + Vehicle	SRP + ARESTIN
≥ 5 mm (n)	-1.04 mm (124)	-0.90 mm (123)	-1.20 mm* (121)	-1.32 mm (126)	-1.30 mm (126)	-1.63 mm* (128)
≥ 6 mm (n)	-0.91 mm (34)	-0.77 mm (46)	-1.40 mm* (45)	-1.33 mm (37)	-1.46 mm (40)	-1.69 mm* (25)
≥ 7 mm (n)	-1.10 mm (4)	-0.46 mm (5)	-1.91 mm (3)	-1.72 mm (3)	-1.11 mm (3)	-2.84 mm (2)

*Statistically significant comparison between SRP + ARESTIN and SRP alone

The combined data from these 2 studies also show that for pockets 5 mm to 7 mm at baseline, greater reductions in pocket depth occurred in pockets that were deeper at baseline.

INDICATIONS AND USE

ARESTIN is indicated as an adjunct to scaling and root planing procedures for reduction of pocket depth in patients with adult periodontitis. ARESTIN may be used as part of a periodontal maintenance program which includes good oral hygiene and scaling and root planing.

CONTRAINDICATIONS

ARESTIN should not be used in any patient who has a known sensitivity to minocycline or tetracyclines.

WARNINGS

THE USE OF DRUGS OF THE TETRACYCLINE CLASS DURING TOOTH DEVELOPMENT (LAST HALF OF PREGNANCY, INFANCY, AND CHILDHOOD TO THE AGE OF 8 YEARS) MAY CAUSE PERMANENT DISCOLORATION OF THE TEETH (YELLOW-GRAY BROWN). This adverse reaction is more common during long-term use of the drugs, but has been observed following repeated short-term courses. Enamel hypoplasia has also been reported. TETRACYCLINE DRUGS, THEREFORE, SHOULD NOT BE USED IN THIS AGE GROUP, OR IN PREGNANT OR NURSING WOMEN, UNLESS THE POTENTIAL BENEFITS ARE CONSIDERED TO OUTWEIGH THE POTENTIAL RISKS. Results of animal studies indicate that tetracyclines cross the placenta, are found in fetal tissues, and can have toxic effects on the developing fetus (often related to retardation of skeletal development). Evidence of embryotoxicity has also been noted in animals treated early in pregnancy. If any tetracyclines are used during pregnancy, or if the patient becomes pregnant while taking this drug, the patient should be apprised of the potential hazard to the fetus. Photosensitivity manifested by an exaggerated sunburn reaction has been observed in some individuals taking tetracyclines. Patients apt to be exposed to direct sunlight or ultraviolet light should be advised that this reaction can occur with tetracycline drugs, and treatment should be discontinued at the first evidence of skin erythema.

PRECAUTIONS

Hypersensitivity Reactions and Hypersensitivity Syndrome

The following adverse events have been reported with minocycline products when taken orally. Hypersensitivity reactions and hypersensitivity syndrome that included, but were not limited to anaphylaxis, anaphylactoid reaction, angioneurotic edema, urticaria, rash, eosinophilia, and one or more of the following: hepatitis, pneumonitis, nephritis, myocarditis, and pericarditis may be present. Swelling of the face, pruritus, fever and lymphadenopathy have been reported with the use of ARESTIN. Some of these reactions were serious. Post-marketing cases of anaphylaxis and serious skin reactions such as Stevens-Johnson syndrome and erythema multiforme have been reported with oral minocycline.

Autoimmune Syndromes

Tetracyclines, including oral minocycline, have been associated with the development of autoimmune syndromes including a lupus-like syndrome manifested by arthralgia, myalgia, rash, and swelling. Sporadic cases of serum sickness-like reaction have presented shortly after oral minocycline use, manifested by fever, rash, arthralgia, lymphadenopathy and malaise. In symptomatic patients, liver function tests, ANA, CBC, and other appropriate tests should be performed to evaluate the patients. No further treatment with ARESTIN should be administered to the patient.

The use of ARESTIN in an acutely abscessed periodontal pocket has not been studied and is not recommended.

While no overgrowth by opportunistic microorganisms, such as yeast, was noted during clinical studies, as with other antimicrobials, the use of ARESTIN may result in overgrowth of non-susceptible microorganisms including fungi. The effects of treatment for greater than 6 months have not been studied.

ARESTIN should be used with caution in patients having a history of predisposition to oral candidiasis. The safety and effectiveness of ARESTIN have not been established for the treatment of periodontitis in patients with coexistent oral candidiasis.

ARESTIN has not been clinically tested in immunocompromised patients (such as those immunocompromised by diabetes, chemotherapy, radiation therapy, or infection with HIV).

If superinfection is suspected, appropriate measures should be taken.

ARESTIN has not been clinically tested in pregnant women.

ARESTIN has not been clinically tested for use in the regeneration of alveolar bone, either in preparation for or in conjunction with the placement of endosseous (dental) implants or in the treatment of failing implants.

Information for Patients

After treatment, patients should avoid chewing hard, crunchy, or sticky foods (i.e., carrots, taffy, and gum) with the treated teeth for 1 week, as well as avoid touching treated areas. Patients should also postpone the use of interproximal cleaning devices around the treated sites for 10 days after administration of ARESTIN. Patients should be advised that although some mild to moderate sensitivity is expected during the first week after SRP and administration of ARESTIN, they should notify the dentist promptly if pain, swelling, or other problems occur. Patients should be notified to inform the dentist if itching, swelling, rash, papules, reddening, difficulty breathing, or other signs and symptoms of possible hypersensitivity occur.

Carcinogenicity, Mutagenicity, Impairment of Fertility

Dietary administration of minocycline in long-term tumorigenicity studies in rats resulted in evidence of thyroid tumor production. Minocycline has also been found to produce thyroid hyperplasia in rats and dogs. In addition, there has been evidence of oncogenic activity in rats in studies with a related antibiotic, oxytetracycline (i.e., adrenal and pituitary tumors). Minocycline demonstrated no potential to cause genetic toxicity in a battery of assays which included a bacterial reverse mutation assay (Ames test), an *in vitro* mammalian cell gene mutation test (L5178Y/TK+/- mouse lymphoma assay), an *in vitro* mammalian chromosome aberration test, and an *in vivo* micronucleus assay conducted in ICR mice.

Fertility and general reproduction studies have provided evidence that minocycline impairs fertility in male rats.

Pregnancy

Teratogenic Effects: (See WARNINGS.)

Labor and Delivery

The effects of tetracyclines on labor and delivery are unknown.

Nursing Mothers

Tetracyclines are excreted in human milk. Because of the potential for serious adverse reactions in nursing infants from the tetracyclines, a decision should be made whether to discontinue nursing or discontinue the drug, taking into account the importance of the drug to the mother (see WARNINGS).

Pediatric Use

Since adult periodontitis does not affect children, the safety and effectiveness of ARESTIN in pediatric patients cannot be established.

ADVERSE REACTIONS

The most frequently reported non-dental, treatment-emergent adverse events in the 3 multicenter US trials were headache, infection, flu syndrome, and pain.

Table 5: Adverse Events (AEs) Reported in $\geq 3\%$ of the Combined Clinical Trial Population of 3 Multicenter US Trials by Treatment Group

	SRP Alone N=250	SRP + Vehicle N=249	SRP + ARESTIN® N=423
Number (%) of Subjects Treatment-emergent AEs	62.4%	71.9%	68.1%
Total Number of AEs	543	589	987
Periodontitis	25.6%	28.1%	16.3%
Tooth Disorder	12.0%	13.7%	12.3%
Tooth Caries	9.2%	11.2%	9.9%
Dental Pain	8.8%	8.8%	9.9%
Gingivitis	7.2%	8.8%	9.2%
Headache	7.2%	11.6%	9.0%
Infection	8.0%	9.6%	7.6%
Stomatitis	8.4%	6.8%	6.4%
Mouth Ulceration	1.6%	3.2%	5.0%
Flu Syndrome	3.2%	6.4%	5.0%
Pharyngitis	3.2%	1.6%	4.3%
Pain	4.0%	1.2%	4.3%
Dyspepsia	2.0%	0	4.0%
Infection Dental	4.0%	3.6%	3.8%
Mucous Membrane Disorder	2.4%	0.8%	3.3%


The change in clinical attachment levels was similar across all study arms, suggesting that neither the vehicle nor ARESTIN compromise clinical attachment.

To report SUSPECTED ADVERSE REACTIONS, contact Valeant Pharmaceuticals North America LLC at 1-800-321-4576 or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch.

DOSAGE AND ADMINISTRATION

ARESTIN is provided as a dry powder, packaged in a unit-dose cartridge with a deformable tip (see **Figure 1**), which is inserted into a spring-loaded cartridge handle mechanism (see **Figure 2**) to administer the product.

The oral health care professional removes the disposable cartridge from its pouch and connects the cartridge to the handle mechanism (see **Figures 3 – 4**). ARESTIN is a variable dose product, dependent on the size, shape, and number of pockets being treated. In US clinical trials, up to 122 unit-dose cartridges were used in a single visit and up to 3 treatments, at 3-month intervals, were administered in pockets with pocket depth of 5 mm or greater.



The administration of ARESTIN does not require local anesthesia. Professional subgingival administration is accomplished by inserting the unit-dose cartridge to the base of the periodontal pocket and then pressing the thumb ring in the handle mechanism to expel the powder while gradually withdrawing the tip from the base of the pocket. The handle mechanism should be sterilized between patients. ARESTIN does not have to be removed, as it is bioresorbable, nor is an adhesive or dressing required.

HOW SUPPLIED

ARESTIN® (minocycline hydrochloride) microspheres, 1 mg is supplied as follows:

NDC 65976-100-01 1 unit-dose cartridge with desiccant in a heat-sealed, foil-laminated pouch

NDC 65976-100-24 12 unit-dose cartridges in 1 tray with desiccant in a heat-sealed, foil-laminated, resealable pouch. There are 2 pouches in each box.

Each unit-dose cartridge contains the product identifier "OP-1."

Storage Conditions

Store at 20° to 25°C (68° to 77°F)/60% RH; excursions permitted to 15° to 30°C (59° to 86°F). Avoid exposure to excessive heat.

Manufactured for:

OraPharma, a division of Valeant Pharmaceuticals North America LLC
Bridgewater, NJ 08807 USA

U.S. Patent Numbers: 6,682,348; 7,699,609; 8,048,021; 9,566,141

Arestin is a trademark of Valeant Pharmaceuticals International, Inc. or its affiliates.

©Valeant Pharmaceuticals North America LLC

Rev. 05/2017

9546401 20001545B